Skip to main content

Table 3 Vaccine efficacy to prevent HIV RNA rebound (phase II primary end point)

From: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

Tat Oyi

0 (n = 12)

11 µg (n = 12)

33 µg (n = 12)

99 µg (n = 10)

Medians (copies/ml)

12,921

20,706

442

9475

Total range

39–0.9 × 106

39–1.2 × 106

39–0.4 × 106

81–0.1 × 106

Log medians

4.1

4.3

2.6

4.0

p values*

 

0.38

0.07

0.50

  1. HIV RNA at M6 after cART interruption at M5
  2. * p values were determined for each vaccine group versus placebo with a one sided Mann and Whitney test without adjustment. Undetectable viraemia (<40 copies/ml) were replaced by 39 (1.6 log) copies/ml
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us